Cue Biopharma is trading 5.31% up at $26.88, rebounding after its 8.46% decline on August 31, 2026, with no new company-specific announcement or clearly attributable catalyst identified for September 1, 2026.
- The broader backdrop is unfavorable, with global stocks pressured by rising bond yields, higher oil prices, geopolitical tensions, and renewed interest-rate concerns.
- Reuters reported Japan’s 10-year yield reaching 3%, its highest level since 1996.
- The rebound remains unexplained rather than clearly linked to macro sentiment.